Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
Related CLVSClovis Oncology Could Pass $100 By Year-End: Here’s WhyClovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLCClovis Oncology: Don’t Discount Rociletinib’s Chances Against AZD9291(Seeking Alpha)Related EPZMBenzinga’s Top DowngradesH.C. Wainwright Destroys Epizyme Price Target, Sees ‘No Material Value Drivers’A new report by Mizuho analyst Peter Lawson focuses on biotech stocks with major catalysts […]
Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
Harness Biotech Stock Volatility with an Options StrategyCompanies / BioTechAug 13, 2015 – 10:27 PM GMTBy: TLSReportVolatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That’s the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital. Can you grow a portfolio if some of your more successful names […]
Submitted by Joseph Calhoun via Alhambra Investment Partners,
All that we see or seem is but a dream within a dream.
Edgar Allan Poe
All things are subject to interpretation. Whichever interpretation prevails at a given time is a function of power not truth.
Friedrich Nietzsche
I was walking down the street wearing glasses when the prescription ran out.
Steven Wright
I think one of the hardest […]
SummaryAs an update from my previous article, I am reviewing some European biotech picks and introducing new favorites.
Owing to strong fundamentals and an increasing number of significant deals in the sector, a technologically diversified, European biotech portfolio makes more sense now than ever.
The main investment thesis remains that leading small-cap European biotechs are reaching maturity and present a great value […]
Biotech Indices Can’t Break Through Triple Top
IBB at $365, XBI at $239
Red and green day
Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical Oncology) 2015 in Chicago, IL many “immuno-oncology” stocks were movers.
First look at Rayno Biopharmaceutical Portfolio stocks:
Our big mover […]
On the pages of Investors Alley, Bret Jensen has a history of recommending biotech winners. Today, we’re following up on five of Bret’s most promising biotech recommendations that have staged big gains and could still be in the early innings of significant rallies. These stocks are still strong buys.The small biotech sector is one of the most volatile sectors of […]
Stock Market Deflationary Outcome. It’s ComingStock-Markets / Stock Markets 2015May 08, 2015 – 10:39 AM GMTBy: Tim_WoodThe reality is that ever since the 2000 top, both the economy and the stock market have been trying to deflate. It has been these deflationary forces that the Money Masters have been fighting. In the process, they created the housing bubble, the 2007 […]
REUTERS/China Daily
Shares of $875 million biotech company Ocular Therapeutix were down as much as 30% in after hours trade on Monday after the company reported clinical trial results that disappointed. The company announced Monday that topline data for its lead drug candidate, a treatment for ocular inflammation following cataract surgery, met one of its two primary endpoints. The company said both endpoints needed […]
